Greater Awareness Needed for Potential of T2DM Remission

Share this content:
Greater Awareness Needed for Potential of T2DM Remission
Greater Awareness Needed for Potential of T2DM Remission

THURSDAY, Sept. 14, 2017 (HealthDay News) -- For many patients with type 2 diabetes, remission can be achieved with sustained weight loss of ~15 kg, yet this often flies under the radar for patients and clinicians alike, according to an analysis published online Sept. 13 in The BMJ.

Noting that type 2 diabetes affects 5 to 10 percent of the U.K. population, and is associated with greater medical costs, Louise McCombie, R.D., from the University of Glasgow in the United Kingdom, and colleagues discuss the importance of achieving remission of type 2 diabetes.

The researchers note that the primary aim of management is lowering blood glucose or glycated hemoglobin (HbA1c) concentrations. Weight loss is associated with extended life expectancy, and weight loss of about 15 kg can induce total biochemical remission. There is currently no consensus on the criteria for diabetes remission; measurement of either HbA1c or blood glucose is sufficient to determine remission. Two test results (usually HbA1c) below the diagnostic threshold, at least two months apart, can confirm remission. Patients in remission should be monitored regularly with annual testing. Although no study has reported outcomes for those who achieve remission, good glycemic control is associated with improved microvascular outcomes. Patients are rarely recorded as being in remission, possibly because few patients are attempting or achieving remission.

"It is in everybody's interest to reclassify people with type 2 diabetes when they become non-diabetic," the authors write. "Official guidelines and international consensus for recording diabetes in remission are needed."

Two authors provide consultancy to Counterweight.

Abstract/Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »